- Home
- OP vs BLRX Comparison
OP vs BLRX Comparison
Compare OP & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OP
- BLRX
- Stock Information
- Founded
- OP 2021
- BLRX 2003
- Country
- OP Greece
- BLRX Israel
- Employees
- OP N/A
- BLRX N/A
- Industry
- OP
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- OP
- BLRX Health Care
- Exchange
- OP Nasdaq
- BLRX Nasdaq
- Market Cap
- OP 14.3M
- BLRX 17.0M
- IPO Year
- OP N/A
- BLRX 2011
- Fundamental
- Price
- OP $0.07
- BLRX $3.74
- Analyst Decision
- OP
- BLRX Strong Buy
- Analyst Count
- OP 0
- BLRX 2
- Target Price
- OP N/A
- BLRX $19.00
- AVG Volume (30 Days)
- OP 61.1M
- BLRX 39.3K
- Earning Date
- OP 08-08-2025
- BLRX 08-14-2025
- Dividend Yield
- OP N/A
- BLRX N/A
- EPS Growth
- OP N/A
- BLRX N/A
- EPS
- OP N/A
- BLRX N/A
- Revenue
- OP $19,435,000.00
- BLRX $17,251,000.00
- Revenue This Year
- OP N/A
- BLRX N/A
- Revenue Next Year
- OP N/A
- BLRX N/A
- P/E Ratio
- OP N/A
- BLRX N/A
- Revenue Growth
- OP N/A
- BLRX 1.19
- 52 Week Low
- OP $0.06
- BLRX $2.30
- 52 Week High
- OP $3.17
- BLRX $30.66
- Technical
- Relative Strength Index (RSI)
- OP 32.16
- BLRX 43.17
- Support Level
- OP $0.09
- BLRX $3.50
- Resistance Level
- OP $0.12
- BLRX $3.95
- Average True Range (ATR)
- OP 0.01
- BLRX 0.28
- MACD
- OP 0.04
- BLRX 0.01
- Stochastic Oscillator
- OP 3.41
- BLRX 47.56
About OP OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary. The company includes Dry Bulk segment and Tanker segment. Majority of revenue is Dry Bulk segment.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.